Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer

PURPOSE: Immune checkpoint inhibitors (ICI) are a promising treatment, but may cause hyperprogressive disease and early death. The present study investigated early mortality factors in ICI monotherapy for lung cancer. PATIENTS AND METHODS: We retrospectively reviewed all patients diagnosed with adva...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Eiji, Kondo, Kensuke, Okano, Yoshio, Kunishige, Michihiro, Kondo, Yoshihiro, Kadota, Naoki, Machida, Hisanori, Hatakeyama, Nobuo, Naruse, Keishi, Ogino, Hirokazu, Nokihara, Hiroshi, Shinohara, Tsutomu, Nishioka, Yasuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314836/
https://www.ncbi.nlm.nih.gov/pubmed/35871700
http://dx.doi.org/10.1007/s00432-022-04215-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314836/
https://www.ncbi.nlm.nih.gov/pubmed/35871700
http://dx.doi.org/10.1007/s00432-022-04215-7

Ejemplares similares